CVS Health Co. (NYSE:CVS) Receives Average Recommendation of “Moderate Buy” from Analysts

CVS Health Co. (NYSE:CVS) has been given a consensus recommendation of “Moderate Buy” by the nineteen research firms that are covering the company, Marketbeat reports. Six research analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $69.12.

CVS has been the subject of several analyst reports. UBS Group raised their price target on shares of CVS Health from $60.00 to $62.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. StockNews.com lowered CVS Health from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $62.00 price objective on shares of CVS Health in a research note on Tuesday, October 1st. Wells Fargo & Company raised shares of CVS Health from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $60.00 to $66.00 in a research report on Monday, November 18th. Finally, Mizuho reduced their price objective on shares of CVS Health from $73.00 to $66.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th.

Institutional Trading of CVS Health

Hedge funds and other institutional investors have recently bought and sold shares of the business. Banco Santander S.A. increased its holdings in CVS Health by 5.1% during the 2nd quarter. Banco Santander S.A. now owns 88,638 shares of the pharmacy operator’s stock worth $5,235,000 after purchasing an additional 4,331 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in CVS Health by 7.1% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 251,776 shares of the pharmacy operator’s stock valued at $14,870,000 after buying an additional 16,677 shares during the last quarter. F M Investments LLC purchased a new position in CVS Health during the 2nd quarter worth $1,662,000. Crewe Advisors LLC grew its stake in shares of CVS Health by 104.6% in the 2nd quarter. Crewe Advisors LLC now owns 1,019 shares of the pharmacy operator’s stock worth $60,000 after acquiring an additional 521 shares in the last quarter. Finally, Smith Salley Wealth Management purchased a new stake in shares of CVS Health in the second quarter valued at about $1,190,000. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Up 2.2 %

Shares of CVS opened at $44.89 on Wednesday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.59 and a current ratio of 0.80. CVS Health has a 52 week low of $43.56 and a 52 week high of $83.25. The stock has a market capitalization of $56.49 billion, a price-to-earnings ratio of 11.39, a PEG ratio of 0.85 and a beta of 0.54. The stock has a fifty day moving average of $53.54 and a 200-day moving average of $57.41.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.01. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. The firm had revenue of $95.43 billion for the quarter, compared to analyst estimates of $92.72 billion. During the same period last year, the firm posted $2.21 earnings per share. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. As a group, sell-side analysts anticipate that CVS Health will post 5.32 earnings per share for the current fiscal year.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.